Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt revenue growth has been varied year-over-year.

What is LGNZZ's revenue growth rate?

Historical revenue data is available for Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt to analyze growth trends.

How fast is LGNZZ earnings growing?

Earnings growth data is available for Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt analysis.

What is LGNZZ's profit margin?

Profit margin data is available for Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt.

LGNZZ Revenue & Earnings Growth Analysis 2026 - Is Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt Growing?

Growth Summary

Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt (LGNZZ) has experienced challenges in growth. The company operates in the Technology sector, specifically in the Software industry.

Over the past 4 years, Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt has achieved a revenue compound annual growth rate (CAGR) of 35.1%, while earnings have grown at 45.7% CAGR.

Latest Revenue

$167.13M

Net Income

$-4032000.00

5-Year Revenue CAGR

35.1%

4 years of data

Net Margin

N/A

Latest period

Revenue Growth Over Time

Historical revenue and profitability trends for Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt

The chart above illustrates Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.

Year-over-Year Growth Rates

Annual percentage change in revenue and earnings

Growth rates provide insight into the momentum of Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt's business.

Profit Margin Trends

How efficiently Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt converts revenue into profit

Understanding Profit Margins

Profit margins reveal how much of each dollar of revenue Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt retains at different stages:

Gross Margin (N/A%): What remains after direct production costs
Operating Margin (N/A%): Profit from core operations before interest and taxes
Net Margin (N/A%): Final profit after all expenses

Future Growth Outlook

Analyst estimates and forward-looking indicators

What Analysts Are Saying

Wall Street analysts project Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt to continue focusing on sustainable operations.

Growth Analysis Conclusion

Based on our comprehensive analysis, Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt (LGNZZ) demonstrates declining growth characteristics.

Key Takeaways:

Revenue Growth:, 35.1% CAGR over 4 years
Profitability: shows the company is investing in growth over short-term profits
Efficiency:

Investment Considerations

This growth analysis provides a comprehensive view of Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.